An alternative route to pertussis protection?
[...]the relative efficacy of BPZE1 versus Tdap against clinical pertussis is unclear, because no antibody correlate of protection has been established. [...]we agree with the authors' assessment that BPZE1 could help to avert B pertussis infections, and could lead to reduced transmission and d...
Gespeichert in:
| Veröffentlicht in: | The Lancet (British edition) 2023-03, Vol.401 (10379), p.800-801 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 801 |
|---|---|
| container_issue | 10379 |
| container_start_page | 800 |
| container_title | The Lancet (British edition) |
| container_volume | 401 |
| creator | Edwards, Kathryn M Decker, Michael D |
| description | [...]the relative efficacy of BPZE1 versus Tdap against clinical pertussis is unclear, because no antibody correlate of protection has been established. [...]we agree with the authors' assessment that BPZE1 could help to avert B pertussis infections, and could lead to reduced transmission and diminished epidemic cycles, but more studies are required to ensure the durability of the immune response and to establish whether BPZE1's less robust humoral response impairs the vaccine's disease prevention. KME has received grants from the US National Institutes of Health (mentoring young investigators) and the Centers for Disease Control and Prevention (assessing vaccine safety), has consulted for Bionet and IBM, and has served on data safety and monitoring boards for Sanofi, X-4 Pharma, Seqirus, Moderna, Pfizer, Merck, and Roche. |
| doi_str_mv | 10.1016/S0140-6736(23)00225-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2786098135</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0140673623002258</els_id><sourcerecordid>2785174518</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-2f848f3c1f83ea2e6fcc2f1890701836fe293b4565b5a6722991911ff69dc2c83</originalsourceid><addsrcrecordid>eNqFkEtLAzEUhYMotlZ_gjLgpi5G85hkklUpxRcUXKjgLkzTG0iZTmqSKfjvnWmrCzeu7uY753A_hC4JviWYiLtXTAqci5KJMWU3GFPKc3mEhqQoi5wX5ccxGv4iA3QW4wpjXAjMT9GACYUFY2qI8mmTVXWC0FTJbSELvk2QJZ9tIKQ2RhezTfAJTHK-mZyjE1vVES4Od4TeH-7fZk_5_OXxeTad54YplnJqZSEtM8RKBhUFYY2hlkiFS0wkExaoYouCC77glSgpVYooQqwVammokWyExvvebvuzhZj02kUDdV014NuoaSkFVpIw3qHXf9CVb7tv6h3FSVlw0hfyPWWCjzGA1Zvg1lX40gTr3qfe-dS9LE2Z3vnUfe7q0N4u1rD8Tf0I7IDJHoBOx9ZB0NE4aAwsXeik6aV3_0x8A_4FgoE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2785174518</pqid></control><display><type>article</type><title>An alternative route to pertussis protection?</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Edwards, Kathryn M ; Decker, Michael D</creator><creatorcontrib>Edwards, Kathryn M ; Decker, Michael D</creatorcontrib><description>[...]the relative efficacy of BPZE1 versus Tdap against clinical pertussis is unclear, because no antibody correlate of protection has been established. [...]we agree with the authors' assessment that BPZE1 could help to avert B pertussis infections, and could lead to reduced transmission and diminished epidemic cycles, but more studies are required to ensure the durability of the immune response and to establish whether BPZE1's less robust humoral response impairs the vaccine's disease prevention. KME has received grants from the US National Institutes of Health (mentoring young investigators) and the Centers for Disease Control and Prevention (assessing vaccine safety), has consulted for Bionet and IBM, and has served on data safety and monitoring boards for Sanofi, X-4 Pharma, Seqirus, Moderna, Pfizer, Merck, and Roche.</description><identifier>ISSN: 0140-6736</identifier><identifier>EISSN: 1474-547X</identifier><identifier>DOI: 10.1016/S0140-6736(23)00225-8</identifier><identifier>PMID: 36906339</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Administration, Intranasal ; Antibodies ; Antigens ; Babies ; Diphtheria ; Disease control ; Humans ; Immune response ; Immune response (humoral) ; Infections ; Pertussis ; Pertussis Vaccine ; Pharmaceuticals ; Prevention ; Safety ; Tetanus ; Vaccines ; Whooping cough ; Whooping Cough - prevention & control</subject><ispartof>The Lancet (British edition), 2023-03, Vol.401 (10379), p.800-801</ispartof><rights>2023 Elsevier Ltd</rights><rights>2023. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-2f848f3c1f83ea2e6fcc2f1890701836fe293b4565b5a6722991911ff69dc2c83</citedby><cites>FETCH-LOGICAL-c393t-2f848f3c1f83ea2e6fcc2f1890701836fe293b4565b5a6722991911ff69dc2c83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2785174518?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>315,781,785,3551,27928,27929,45999,64389,64391,64393,72473</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36906339$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Edwards, Kathryn M</creatorcontrib><creatorcontrib>Decker, Michael D</creatorcontrib><title>An alternative route to pertussis protection?</title><title>The Lancet (British edition)</title><addtitle>Lancet</addtitle><description>[...]the relative efficacy of BPZE1 versus Tdap against clinical pertussis is unclear, because no antibody correlate of protection has been established. [...]we agree with the authors' assessment that BPZE1 could help to avert B pertussis infections, and could lead to reduced transmission and diminished epidemic cycles, but more studies are required to ensure the durability of the immune response and to establish whether BPZE1's less robust humoral response impairs the vaccine's disease prevention. KME has received grants from the US National Institutes of Health (mentoring young investigators) and the Centers for Disease Control and Prevention (assessing vaccine safety), has consulted for Bionet and IBM, and has served on data safety and monitoring boards for Sanofi, X-4 Pharma, Seqirus, Moderna, Pfizer, Merck, and Roche.</description><subject>Administration, Intranasal</subject><subject>Antibodies</subject><subject>Antigens</subject><subject>Babies</subject><subject>Diphtheria</subject><subject>Disease control</subject><subject>Humans</subject><subject>Immune response</subject><subject>Immune response (humoral)</subject><subject>Infections</subject><subject>Pertussis</subject><subject>Pertussis Vaccine</subject><subject>Pharmaceuticals</subject><subject>Prevention</subject><subject>Safety</subject><subject>Tetanus</subject><subject>Vaccines</subject><subject>Whooping cough</subject><subject>Whooping Cough - prevention & control</subject><issn>0140-6736</issn><issn>1474-547X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkEtLAzEUhYMotlZ_gjLgpi5G85hkklUpxRcUXKjgLkzTG0iZTmqSKfjvnWmrCzeu7uY753A_hC4JviWYiLtXTAqci5KJMWU3GFPKc3mEhqQoi5wX5ccxGv4iA3QW4wpjXAjMT9GACYUFY2qI8mmTVXWC0FTJbSELvk2QJZ9tIKQ2RhezTfAJTHK-mZyjE1vVES4Od4TeH-7fZk_5_OXxeTad54YplnJqZSEtM8RKBhUFYY2hlkiFS0wkExaoYouCC77glSgpVYooQqwVammokWyExvvebvuzhZj02kUDdV014NuoaSkFVpIw3qHXf9CVb7tv6h3FSVlw0hfyPWWCjzGA1Zvg1lX40gTr3qfe-dS9LE2Z3vnUfe7q0N4u1rD8Tf0I7IDJHoBOx9ZB0NE4aAwsXeik6aV3_0x8A_4FgoE</recordid><startdate>20230311</startdate><enddate>20230311</enddate><creator>Edwards, Kathryn M</creator><creator>Decker, Michael D</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TT</scope><scope>0TZ</scope><scope>0U~</scope><scope>3V.</scope><scope>7QL</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88C</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>KB~</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>20230311</creationdate><title>An alternative route to pertussis protection?</title><author>Edwards, Kathryn M ; Decker, Michael D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-2f848f3c1f83ea2e6fcc2f1890701836fe293b4565b5a6722991911ff69dc2c83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Administration, Intranasal</topic><topic>Antibodies</topic><topic>Antigens</topic><topic>Babies</topic><topic>Diphtheria</topic><topic>Disease control</topic><topic>Humans</topic><topic>Immune response</topic><topic>Immune response (humoral)</topic><topic>Infections</topic><topic>Pertussis</topic><topic>Pertussis Vaccine</topic><topic>Pharmaceuticals</topic><topic>Prevention</topic><topic>Safety</topic><topic>Tetanus</topic><topic>Vaccines</topic><topic>Whooping cough</topic><topic>Whooping Cough - prevention & control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Edwards, Kathryn M</creatorcontrib><creatorcontrib>Decker, Michael D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>News PRO</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Global News & ABI/Inform Professional</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>British Nursing Index</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Newsstand Professional</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Edwards, Kathryn M</au><au>Decker, Michael D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An alternative route to pertussis protection?</atitle><jtitle>The Lancet (British edition)</jtitle><addtitle>Lancet</addtitle><date>2023-03-11</date><risdate>2023</risdate><volume>401</volume><issue>10379</issue><spage>800</spage><epage>801</epage><pages>800-801</pages><issn>0140-6736</issn><eissn>1474-547X</eissn><abstract>[...]the relative efficacy of BPZE1 versus Tdap against clinical pertussis is unclear, because no antibody correlate of protection has been established. [...]we agree with the authors' assessment that BPZE1 could help to avert B pertussis infections, and could lead to reduced transmission and diminished epidemic cycles, but more studies are required to ensure the durability of the immune response and to establish whether BPZE1's less robust humoral response impairs the vaccine's disease prevention. KME has received grants from the US National Institutes of Health (mentoring young investigators) and the Centers for Disease Control and Prevention (assessing vaccine safety), has consulted for Bionet and IBM, and has served on data safety and monitoring boards for Sanofi, X-4 Pharma, Seqirus, Moderna, Pfizer, Merck, and Roche.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>36906339</pmid><doi>10.1016/S0140-6736(23)00225-8</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0140-6736 |
| ispartof | The Lancet (British edition), 2023-03, Vol.401 (10379), p.800-801 |
| issn | 0140-6736 1474-547X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2786098135 |
| source | MEDLINE; Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland |
| subjects | Administration, Intranasal Antibodies Antigens Babies Diphtheria Disease control Humans Immune response Immune response (humoral) Infections Pertussis Pertussis Vaccine Pharmaceuticals Prevention Safety Tetanus Vaccines Whooping cough Whooping Cough - prevention & control |
| title | An alternative route to pertussis protection? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T12%3A53%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20alternative%20route%20to%20pertussis%20protection?&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=Edwards,%20Kathryn%20M&rft.date=2023-03-11&rft.volume=401&rft.issue=10379&rft.spage=800&rft.epage=801&rft.pages=800-801&rft.issn=0140-6736&rft.eissn=1474-547X&rft_id=info:doi/10.1016/S0140-6736(23)00225-8&rft_dat=%3Cproquest_cross%3E2785174518%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2785174518&rft_id=info:pmid/36906339&rft_els_id=S0140673623002258&rfr_iscdi=true |